Endeavour Vision leads $25 mln Series D in EndoStim

Endeavour Vision led a $25 million Series D financing round in EndoStim, Inc., a medical device company with a neurostimulation therapy for acid reflux. The treatment is currently available in Europe, Latin America, and Asia Pacific, but has not been approved for sale in the U.S. The funding will go in part towards clinical trials. New investors Wellington Partners and Gimv also participated in the funding.

North AmericaUSBriefs